Free Trial
Dan Brennan

Dan Brennan Analyst Performance

Senior Equity Research Analyst - Managing Director at TD Cowen

Dan Brennan is a stock analyst at TD Cowen, covering 7 publicly traded companies across a range of sectors. Over the past year, Dan Brennan has issued 6 stock ratings, including buy and hold recommendations. While full access to Dan Brennan's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Dan Brennan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 3 Years
Buy Recommendations
85.71% 6 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy85.7%6 ratings
Hold14.3%1 ratings
Sell0.0%0 ratings

Out of 7 total stock ratings issued by Dan Brennan at TD Cowen, the majority (85.7%) have been Buy recommendations, followed by 14.3% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
71.4% of companies on NASDAQ
5 companies
NYSE
28.6% of companies on NYSE
2 companies

Dan Brennan, an analyst at TD Cowen, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
85.7%
Transportation
1 company
14.3%

Dan Brennan of TD Cowen specializes in stock coverage within the Medical sector, with additional focus on Transportation companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
28.6%
MEDICAL SERVICES
2 companies
28.6%
EQUIPMENT RENTAL & LEASING
1 company
14.3%
MED PRODUCTS
1 company
14.3%
MEDICAL INFO SYS
1 company
14.3%

About Dan Brennan

At TD Cowen, Dan is responsible for providing research coverage on a diverse group of companies across the Life Science & Diagnostics Tools’ industry. This includes identifying key investment debates, building financial models, generating research reports, including ‘Ahead of the Curve’ deep dive analysis, making stock recommendations and engaging with clients and TD Cowen representatives. Daniel Brennan is a senior analyst covering Life Science & Diagnostic Tools. Prior to joining TD Cowen, Dan was a Managing Director and senior Life Science & Diagnostic Tools analyst at UBS. Prior to UBS, he was a senior health care analyst at Columbus Circle Investors. Dan also spent 19 years at Morgan Stanley, where he served, amongst other roles, as the health care sector equity sales specialist and later as the senior Life Science & Diagnostic Tools analyst. Mr. Brennan holds a BA in economics from Georgetown University, and an MBA from Harvard University. He is also a CFA® charterholder.
Follow on LinkedIn

Dan Brennan's Ratings History at TD Cowen

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
8/6/2025Boost Price Target$11.54$15.00Buy
CAI International, Inc. stock logo
CAI
CAI International
7/14/2025Initiated Coverage$26.51$32.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
5/1/2025Boost Price Target$48.06$60.00Buy
GeneDx Holdings Corp. stock logo
WGS
GeneDx
5/1/2025Lower Price Target$64.88$110.00Buy
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
3/21/2025Lower Price Target$2.31$2.50Neutral
Tempus AI, Inc. stock logo
TEM
Tempus AI
2/5/2025Reiterated Rating$61.85$74.00Buy